吸入薬の世界市場レポート 2024

吸入薬の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.8%の年間複合成長率（CAGR）で461億9,000万米ドルに成長すると予想されます。予測期間で予想される拡大は、ヘルスケアの増加、生物製剤の需要の高まり、個別化医療への注目の高まり、希少疾病用医薬品に対する規制の支援によるものと考えられます。予測期間中に予想される注目すべき動向には、獣医学、特に高度な呼吸器薬の進歩、技術革新、償還政策の強化が含まれます。

吸入薬市場の予想される成長は、呼吸器疾患の有病率の増加によって促進されると予想されます。呼吸器疾患には、肺、気管支、気管、喉頭、咽頭、鼻道などの重要な構成要素を含む呼吸器系に影響を及ぼす病状が含まれます。 吸入薬は、薬剤を肺に直接届けることにより、さまざまな呼吸器疾患に対する重要かつ効果的な治療オプションとして機能します。たとえば、2023年6月のオーストラリア保健福祉研究所のデータでは、2021年のオーストラリアにおける慢性呼吸器疾患による死亡者数は約6,551人で、これは人口10万人あたり135人に相当し、全死亡者数の27.1%を占めたと報告されています。慢性閉塞性肺疾患（COPD）は、基礎疾患による呼吸器系死亡の2.6%に寄与しました。したがって、呼吸器疾患の有病率の上昇は、将来の吸入薬市場の原動力となると予想されます。

個別化医療がますます重視されるようになり、近い将来、吸入薬市場の成長が促進される見込みです。個別化医療は精密医療としても知られ、患者の遺伝子、環境、ライフスタイルの個人差を考慮した新しい治療アプローチを表します。吸入可能な医薬品の文脈では、個別化医療には、個々の遺伝的要因、バイオマーカー、および臨床的要因に基づいて治療を調整することが含まれます。このアプローチは、吸入薬物療法の有効性と呼吸器ケアにおける全体的な患者の満足度を高める可能性があります。たとえば、2023年 2月のPersonalized Medicine Coalitionのデータによると、2022年に米国食品医薬品局が承認した新規医薬品の34%が個別化医療であったことが明らかになりました。さらに、過去8年間の各ライセンスの少なくとも25%をこれらのライセンスが占めていました。したがって、個別化医療への関心の高まりが、吸入薬市場の促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 市場促進要因・市場抑制要因
  • 市場促進要因
  • 市場抑制要因
• 市場規模と成長実績、2018～2023年
• 市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の吸入薬市場、製品別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• エアロゾル
• ドライパウダー製剤
• スプレー
• 世界の吸入薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 病院薬局
• 薬局店舗
• その他
• 世界の吸入薬市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 呼吸器疾患
• 非呼吸器疾患
• 世界の吸入薬市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 成人
• 小児
• 高齢者

第7章 地域および国の分析

• 世界の吸入薬市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の吸入薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 吸入薬市場の競合情勢
• 吸入薬市場の企業プロファイル
  • Pfizer Inc.
  • Merck &Co. Inc.
  • Novartis AG
  • Sanofi SA
  • AstraZeneca plc

第31章 その他の大手および革新的な企業

• GlaxoSmithKline Plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Koninklijke Philips NV
• Teva Pharmaceutical Industries Ltd.
• Mylan NV
• Catalent Inc.
• Sumitomo Pharma Co. Ltd.
• Intertek Group plc
• AptarGroup Inc.
• Cipla Inc.
• Glenmark Pharmaceuticals Inc.
• Piramal Pharma Ltd.
• Zambon SpA
• Sunovion Pharmaceuticals Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Inhalable drugs are medications administered directly into the respiratory system through inhalation for a rapid onset of therapeutic effects. These drugs are formulated to be inhaled into the lungs, facilitating swift absorption into the bloodstream.

The primary forms of inhalable drugs include aerosols, dry powder formulations, and sprays. An aerosol is a suspension of particles or droplets in the air, encompassing airborne dust, fog, odors, or smoke. These products are distributed through various channels, including hospital pharmacies, pharmacy stores, and others. They find applications in treating both respiratory and non-respiratory diseases, catering to diverse end-users such as adults, pediatrics, and geriatrics.

The inhalable drug market research report is one of a series of new reports from The Business Research Company that provides inhalable drug market statistics, including the inhalable drug industry's global market size, regional shares, competitors with an inhalable drug market share, detailed inhalable drug market segments, market trends, and opportunities, and any further data you may need to thrive in the inhalable drug industry. This inhalable drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The inhalable drugs market size has grown strongly in recent years. It will grow from $33.29 billion in 2023 to $35.48 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The rise observed in the historical period can be ascribed to the growing geriatric population, a preference among patients for non-invasive treatments, heightened emphasis on respiratory health, and the expansion of emerging markets.

The inhalable drugs market size is expected to see strong growth in the next few years. It will grow to $46.19 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The anticipated expansion in the forecast period can be credited to the increasing expenditure on healthcare, a rising demand for biologics, a heightened focus on personalized medicine, and regulatory backing for orphan drugs. Noteworthy trends expected in the forecast period encompass advancements in veterinary medicine, particularly in advanced respiratory drugs, technological innovations, and enhancements in reimbursement policies.

The expected growth in the inhalable drug market is anticipated to be propelled by the increasing prevalence of respiratory diseases. Respiratory diseases encompass medical conditions affecting the respiratory system, which includes vital components such as the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Inhalable drugs serve as a crucial and effective treatment option for various respiratory disorders by delivering medication directly to the lungs. For instance, data from the Australian Institute of Health and Welfare in June 2023 reported around 6,551 deaths, equivalent to 135 deaths per 100,000 population, due to respiratory chronic conditions in Australia in 2021, constituting 27.1% of all deaths. Chronic obstructive pulmonary disease (COPD) contributed to 2.6% of underlying-cause respiratory deaths. Therefore, the rising prevalence of respiratory diseases is expected to be a driving force for the future inhalable drug market.

The increasing emphasis on personalized medicine is poised to propel the growth of the inhalable drug market in the foreseeable future. Personalized medicine, also known as precision medicine, represents a novel treatment approach that considers individual variations in patients' genes, environments, and lifestyles. In the context of inhalable pharmaceuticals, personalized medicine involves tailoring therapies based on individual genetic, biomarker, and clinical factors. This approach has the potential to enhance the effectiveness of inhalable medication therapy and overall patient satisfaction in respiratory care. For example, data from the Personalized Medicine Coalition in February 2023 revealed that personalized medications constituted 34% of new pharmaceuticals approved by the US Food and Drug Administration in 2022. Moreover, they had accounted for at least 25% of licenses in each of the previous eight years. Hence, the growing emphasis on personalized medicine serves as a driving factor for the inhalable drug market.

Product innovations have emerged as a significant trend gaining traction in the inhalable drug market, with major companies strategically focusing on advancing inhalable drugs to maintain their market standing. A notable example is DMV-Fonterra Excipients GmbH & Co. KG, a Germany-based pharmaceutical company, which, in July 2022, expanded its dry powder inhalation (DPI) portfolio by introducing Lactohale 400. This new grade, customizable to meet specific pharmaceutical company requirements, was developed collaboratively with formulators to ensure optimal patient outcomes. Lactohale 400, a crushed, dry lactose type, caters to DPI applications requiring high flow and cohesiveness, offering different aerosolization performance than commonly used lactose carriers of the same particle size due to its anhydrous nature.

Major companies are increasingly adopting a strategic partnership approach to develop inhaled medications, particularly for treating lung infections. This collaborative strategy involves leveraging each other's strengths and resources for mutual benefits. A noteworthy partnership was announced in November 2023 between Qnovia, Inc., a US-based pharmaceutical and medtech company, and the University of Virginia (UVA), a US-based public research university. This collaboration aims to advance novel inhaled medication alternatives for the treatment of bacterial infections in the lungs by combining Qnovia's expertise in inhaled medicine delivery with UVA's exclusive array of antimicrobial peptides. The joint effort targets antibiotic-resistant and biodefense germs that can cause life-threatening illnesses, introducing two new assets-QN-05 for pneumonia and QN-06 for lung infections caused by Bacillus anthracis, the organism triggering anthrax-into Qnovia's development pipeline.

In August 2021, Philip Morris International Inc., a US-based tobacco company, acquired OtiTopic Inc. for $1.2 billion. This acquisition underscores Philip Morris' commitment to utilizing its expertise, scientific knowledge, and inhalation capabilities for developing therapeutic inhaled treatments and other drugs, including Beyond Nicotine. OtiTopic Inc., a US-based inhalation drug development company, aligns with Philip Morris International's strategic vision for diversification and innovation in the inhalable drug market.

Major companies operating in the inhalable drugs market report are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH,Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Mylan N.V., Catalent Inc., Sumitomo Pharma Co. Ltd., Intertek Group plc, AptarGroup Inc., Cipla Inc., Glenmark Pharmaceuticals Inc., Piramal Pharma Ltd., Zambon S.p.A., Sunovion Pharmaceuticals Inc., Nelson Laboratories LLC, Vectura Group Limited, Abiogen Pharma, Quotient Sciences, AeroGen Pharma, CareFusion Corporation, Alaxia S.A.S., Pharmaxis Ltd., Avalyn Pharma Inc., TFF Pharmaceuticals Inc.

North America was the largest region in the inhalable drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the inhalable drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The inhalable drugs market consists of sales of orally inhaled drug products, corticosteroids, and ribavirin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inhalable Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inhalable drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inhalable drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inhalable drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Product: Aerosol; Dry Powder Formulation; Spray
• 2) By Distribution Channel: Hospital Pharmacy; Pharmacy Stores; Other Distribution Channels
• 3) By Application: Respiratory Diseases; Non-Respiratory Diseases
• 4) By End Users: Adults; Pediatric; Geriatric
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Novartis AG; Sanofi SA; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Inhalable Drugs Market Characteristics

3. Inhalable Drugs Market Trends And Strategies

4. Inhalable Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Inhalable Drugs Market Size and Growth

• 5.1. Global Inhalable Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Inhalable Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Inhalable Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Inhalable Drugs Market Segmentation

• 6.1. Global Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Aerosol
• Dry Powder Formulation
• Spray
• 6.2. Global Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Pharmacy Stores
• Other Distribution Channels
• 6.3. Global Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Respiratory Diseases
• Non-Respiratory Disease
• 6.4. Global Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Adults
• Pediatric
• Geriatric

7. Inhalable Drugs Market Regional And Country Analysis

• 7.1. Global Inhalable Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Inhalable Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Inhalable Drugs Market

• 8.1. Asia-Pacific Inhalable Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Inhalable Drugs Market

• 9.1. China Inhalable Drugs Market Overview
• 9.2. China Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Inhalable Drugs Market

• 10.1. India Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Inhalable Drugs Market

• 11.1. Japan Inhalable Drugs Market Overview
• 11.2. Japan Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Inhalable Drugs Market

• 12.1. Australia Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Inhalable Drugs Market

• 13.1. Indonesia Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Inhalable Drugs Market

• 14.1. South Korea Inhalable Drugs Market Overview
• 14.2. South Korea Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Inhalable Drugs Market

• 15.1. Western Europe Inhalable Drugs Market Overview
• 15.2. Western Europe Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Inhalable Drugs Market

• 16.1. UK Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Inhalable Drugs Market

• 17.1. Germany Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Inhalable Drugs Market

• 18.1. France Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Inhalable Drugs Market

• 19.1. Italy Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Inhalable Drugs Market

• 20.1. Spain Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Inhalable Drugs Market

• 21.1. Eastern Europe Inhalable Drugs Market Overview
• 21.2. Eastern Europe Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Inhalable Drugs Market

• 22.1. Russia Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Inhalable Drugs Market

• 23.1. North America Inhalable Drugs Market Overview
• 23.2. North America Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Inhalable Drugs Market

• 24.1. USA Inhalable Drugs Market Overview
• 24.2. USA Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Inhalable Drugs Market

• 25.1. Canada Inhalable Drugs Market Overview
• 25.2. Canada Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Inhalable Drugs Market

• 26.1. South America Inhalable Drugs Market Overview
• 26.2. South America Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Inhalable Drugs Market

• 27.1. Brazil Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Inhalable Drugs Market

• 28.1. Middle East Inhalable Drugs Market Overview
• 28.2. Middle East Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Inhalable Drugs Market

• 29.1. Africa Inhalable Drugs Market Overview
• 29.2. Africa Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Inhalable Drugs Market Competitive Landscape And Company Profiles

• 30.1. Inhalable Drugs Market Competitive Landscape
• 30.2. Inhalable Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Merck & Co. Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Sanofi SA
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AstraZeneca plc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Inhalable Drugs Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline Plc
• 31.2. Eli Lilly and Company
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Koninklijke Philips N.V.
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Mylan N.V.
• 31.7. Catalent Inc.
• 31.8. Sumitomo Pharma Co. Ltd.
• 31.9. Intertek Group plc
• 31.10. AptarGroup Inc.
• 31.11. Cipla Inc.
• 31.12. Glenmark Pharmaceuticals Inc.
• 31.13. Piramal Pharma Ltd.
• 31.14. Zambon S.p.A.
• 31.15. Sunovion Pharmaceuticals Inc.

32. Global Inhalable Drugs Market Competitive Benchmarking

33. Global Inhalable Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Inhalable Drugs Market

35. Inhalable Drugs Market Future Outlook and Potential Analysis

• 35.1 Inhalable Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Inhalable Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Inhalable Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer